Rockefeller Capital Management
ATOS icon

Rockefeller Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Rockefeller Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$643 Sell
333
-20
-6% -$91 ﹤0.01% 4570
2026
Q1 		$1.86K Buy
353
+20
+6% +$127 ﹤0.01% 4419
2025
Q4 		$2.95K Hold
333
– – ﹤0.01% 4226
2025
Q3 		$4.33K Buy
+333
New +$4.11K ﹤0.01% 3906
2023
Q1 		– Sell
-333
Closed -$2K – 2110
2022
Q4 		$2K Buy
+333
New +$3.82K ﹤0.01% 3540

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rockefeller Capital Management's ATOS Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Atossa Therapeutics (ATOS) stake by 5.7% in Q2 2026, selling an estimated $91 and leaving 333 shares worth $643. The position accounts for ﹤0.01% of the portfolio, ranked #4570.

Rockefeller Capital Management first reported a position in ATOS in Q4 2022 and has held it in 5 quarters since. The position peaked at $4.33K in Q3 2025. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • Rockefeller Capital Management held 333 shares of Atossa Therapeutics worth $643 as of Q2 2026.
  • Rockefeller Capital Management sold 20 Atossa Therapeutics shares in Q2 2026, an estimated $91.
  • Atossa Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4570 holding.
  • Rockefeller Capital Management first reported a position in Atossa Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • Rockefeller Capital Management's Atossa Therapeutics position peaked at $4.33K in Q3 2025.
  • 31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.